A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.
Jung P, Glaser SP, Han J, Popa A, Pisarsky L, Feng N, Geyer A, Haderk F, Alpar D, Bristow C, Schmittner S, Traexler PE, Mahendra M, Poehn B, Gandhi P, Fiorelli R, Awate S, Budano N, Martin F, Albrecht C, Drobits-Handl B, Anand SS, Kasturirangan S, Trapani F, Schweifer N, Marszalek JR, Tontsch-Grunt U, Pearson M, Heffernan TP, Kraut N, Vellano CP, García-Martínez JM.
Jung P, et al. Among authors: han j.
MAbs. 2024 Jan-Dec;16(1):2438173. doi: 10.1080/19420862.2024.2438173. Epub 2024 Dec 9.
MAbs. 2024.
PMID: 39654063